William Tillett, Yoshiya Tanaka, Diamant Thaci, Barbara Ink, Vanessa Taieb, Heather Edens, Rajan Bajracharya, Jessica A. Walsh
Presenting Author (at EULAR): William Tillett
Abstract or description:We assessed the maintenance of efficacy responses from Week 16 to Week 52 with bimekizumab treatment in patients with active psoriatic arthritis (PsA) who were bDMARD-naïve or had prior inadequate response/intolerance to TNFi, in the phase 3 trials BE OPTIMAL and BE COMPLETE. With bimekizumab treatment, high proportions of Week 16 responders maintained robust efficacy responses at Week 52 or did not lose response at any time point to Week 52 across joint and skin outcomes, including ACR50 and PASI100, demonstrating durable improvement irrespective of prior TNFi use.
Abstract Source: EULAR 2024, 12-15 June, Vienna, Austria
Sponsored by text: These studies were funded by UCB Pharma. All costs associated with development of this presentation were funded by UCB Pharma.
William Tillett, Yoshiya Tanaka, Diamant Thaci, Barbara Ink, Vanessa Taieb, Heather Edens, Rajan Bajracharya, Jessica A. Walsh
Presenting Author (at EULAR): William Tillett
Abstract or description:We assessed the maintenance of efficacy responses from Week 16 to Week 52 with bimekizumab treatment in patients with active psoriatic arthritis (PsA) who were bDMARD-naïve or had prior inadequate response/intolerance to TNFi, in the phase 3 trials BE OPTIMAL and BE COMPLETE. With bimekizumab treatment, high proportions of Week 16 responders maintained robust efficacy responses at Week 52 or did not lose response at any time point to Week 52 across joint and skin outcomes, including ACR50 and PASI100, demonstrating durable improvement irrespective of prior TNFi use.
Abstract Source: EULAR 2024, 12-15 June, Vienna, Austria
Sponsored by text: These studies were funded by UCB Pharma. All costs associated with development of this presentation were funded by UCB Pharma.
